Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies

BACKGROUND: Fostamatinib (R788) is a spleen tyrosine kinase (SYK) inhibitor. The active metabolite of fostamatinib, R406, is primarily metabolized by CYP3A4. OBJECTIVES: The aim of this study was to characterize hepatic microsomal metabolism of R406 and confirm the role of CYP3A4 in R406 metabolism,...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Paul, Gillen, Michael, Millson, David, Oliver, Stuart, Brealey, Clive, Grossbard, Elliott B., Baluom, Muhammad, Lau, David, Sweeny, David, Mant, Tim, Craven, Kelli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4767720/
https://www.ncbi.nlm.nih.gov/pubmed/26739683
http://dx.doi.org/10.1007/s40268-015-0118-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4767720/
https://www.ncbi.nlm.nih.gov/pubmed/26739683
http://dx.doi.org/10.1007/s40268-015-0118-4

Ejemplares similares